Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
212 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00064077 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix |
| completed |
| Phase 3 |
| 513 |
| Gynecologic Oncology GroupNETWORK |
| 1 |
| Oct 17, 2018 |
| clinicaltrials |
| NCT00112489 | Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer | completed | Phase 2 | 55 | Gynecologic Oncology GroupNETWORK | 2 | Sep 25, 2018 | clinicaltrials |
| NCT00114166 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 81 | Gynecologic Oncology GroupNETWORK | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00459290 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00899093 | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy | terminated | — | 2,500 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01275664 | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer | terminated | N/A | 4 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT01295489 | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | — | 39 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT00003702 | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia | completed | Phase 3 | 240 | Gynecologic Oncology GroupNETWORK | 1 | May 15, 2018 | clinicaltrials |
| NCT00003054 | Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 12, 2018 | clinicaltrials |
| NCT00005029 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 12, 2018 | clinicaltrials |
| NCT00096187 | Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy | terminated | Phase 2 | 55 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | completed | — | 247 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01098630 | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | completed | — | 778 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00719303 | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 3 | 1,070 | Gynecologic Oncology GroupNETWORK | 1 | Feb 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00574951 | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00041093 | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00691301 | Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 55 | Gynecologic Oncology GroupNETWORK | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00820898 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00379145 | Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus | completed | Phase 2 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00068406 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva | completed | Phase 2 | 61 | Gynecologic Oncology GroupNETWORK | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00070317 | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer | terminated | N/A | 102 | Gynecologic Oncology GroupNETWORK | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00081263 | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 130 | Gynecologic Oncology GroupNETWORK | 1 | Sep 15, 2017 | clinicaltrials |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | completed | Phase 2 | 171 | Gynecologic Oncology GroupNETWORK | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00460356 | Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes | completed | — | 159 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00521118 | Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors | completed | Phase 2 | 64 | Gynecologic Oncology GroupNETWORK | 2 | Aug 24, 2017 | clinicaltrials |
| NCT00575952 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | completed | Phase 1 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01208467 | Prognostic Biomarkers in Patients With Endometrial Cancer | completed | — | 2,824 | Gynecologic Oncology GroupNETWORK | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00017004 | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | completed | Phase 3 | 114 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00899145 | Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00956670 | Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer(LEG) | unknown | N/A | 1,055 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2017 | clinicaltrials |
| NCT01000259 | Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer | recruiting | — | 174 | Gynecologic Oncology GroupNETWORK | 1 | May 5, 2017 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | completed | — | 275 | Gynecologic Oncology GroupNETWORK | 1 | Oct 28, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials